Cidara Therapeutics, Inc. (CDTX)
NASDAQ: CDTX · Real-Time Price · USD
15.12
-0.51 (-3.26%)
Nov 20, 2024, 4:00 PM EST - Market closed
Cidara Therapeutics Employees
Cidara Therapeutics had 69 employees as of December 31, 2023. The number of employees decreased by 4 or -5.48% compared to the previous year.
Employees
69
Change (1Y)
-4
Growth (1Y)
-5.48%
Revenue / Employee
$647,145
Profits / Employee
-$1,749,754
Market Cap
106.55M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Akoya Biosciences | 330 |
Karyopharm Therapeutics | 325 |
Century Therapeutics | 165 |
Inovio Pharmaceuticals | 122 |
Assembly Biosciences | 65 |
InflaRx | 62 |
Leap Therapeutics | 54 |
Journey Medical | 41 |
CDTX News
- 1 day ago - Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference - GlobeNewsWire
- 13 days ago - Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewsWire
- 21 days ago - Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences - GlobeNewsWire
- 6 weeks ago - Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - GlobeNewsWire
- 2 months ago - Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference - GlobeNewsWire
- 2 months ago - Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza - GlobeNewsWire
- 2 months ago - Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts - GlobeNewsWire
- 2 months ago - Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388 - GlobeNewsWire